FDA Alerts

FDA approves palopegteriparatide as first treatment for hypoparathyroidism in adults

The U.S. Food and Drug Administration (FDA) has approved palopegteriparatide (Yorvipath), as the first and only treatment specifically designed for adults with hypoparathyroidism. This rare endocrine disorder, characterized by insufficient levels of parathyroid hormone, can lead to serious complications, including low calcium levels, muscle cramps, and neurological issues. Approval is...